Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach
Open accessThe DOI matches its Crossref record; 102 of the 103 references it cites were found in a registry or an index.
Abstract
Uterine adenomyosis is a commonly encountered estrogen-dependent disease in reproductive-age women, causing heavy menstrual bleeding, intense pelvic pain, and infertility. Although adenomyosis was previously considered a disease of multiparous women, it is becoming increasingly evident that it also affects younger nulliparous women and may compromise their fertility potential. It is clear that hysterectomy, the standard approach to definitively manage the disease, is not an option for patients wishing to preserve their fertility, so there is an urgent need to develop novel conservative strategies. We searched the current literature for available methods for conservative management of adenomyosis, including both pharmacological and surgical approaches. There is no existing drug that can cure adenomyosis at present, but some off-label treatment options may be used to tackle disease symptoms and improve fertility outcomes. Adenomyosis in patients wishing to conceive can be ‘treated’ by conservative surgery, though these procedures require highly experienced surgeons and pose a considerable risk of uterine rupture during subsequent pregnancies. While currently available options for conservative management of adenomyosis do have some capacity for alleviating symptoms and enhancing patient fertility perspectives, more effective new options are needed, with gonadotropin-releasing hormone antagonists showing encouraging results in preliminary studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Schematic representation of the triple-flap method applied to the anterior and posterior uterine wall. The approach involves complete extraction of the uterine adenomyosis (A–C), followed by reconstruction of the uterine cavity (D–F). An endometrial uterine muscle flap is created by metroplasty and uterine muscle located on the serosal side is used to fill the large uterine wall muscle defect (E,F) (reprinted with permission from [95]).](https://figures.cochat.ai/paper-figures/1fab60a6d4ed43bf9942d9a5f3100fd1/conservative-management-of-uterine-adenomyosis-medical-vs-surgical-approach-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“adenomyosis (AD) and certain subtypes of endometriosis, such as deep endometriosis (DE), do not respond to hormonal treatment as well as ovarian endometrioma (OE) (Stratopoulou et al., 2021; Vannuccini et al., 2022)”
From Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium (2025) · cites this paper as Stratopoulou et al., 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nisolle, M., & Donnez, J. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00191-x · Cited by 1,279 · cited 1×
“Impaired stromal decidualization may constitute another reason, given the frequently encountered resistance to progesterone in adenomyosis patients, a hormone playing a pivotal role in the transition of endometrium to its decidualized state [1,15,82,83].”
BackgroundSelf-citationWhat we know about primary dysmenorrhea today: a critical review
Iacovides, S., Avidon, I., & Baker, F. C. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv039 · Cited by 1,022 · cited 2×
“NSAIDs block cyclooxygenase, suppress prostaglandin, and alleviate uterine hypercontractility, so they relieve pain without treating potential underlying causes, as in case of adenomyosis and endometriosis [8].”
BackgroundUlipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., Ugocsai, G., Mara, M., Jilla, M. P., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103182 · Cited by 680
Self-citationNonsteroidal anti-inflammatory drugs for dysmenorrhoea
Marjoribanks, J., Ayeleke, R. O., Farquhar, C., & Proctor, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001751.pub3 · Cited by 562
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511
The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices
Rivera, R., Yacobson, I., & Grimes, D. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70120-1 · Cited by 400 · cited 1×
“Combined oral contraceptives (COCs) act by inhibiting follicle-stimulating hormone (FSH) and luteinizing hormone (LH), subsequently blocking follicle development and endometrial proliferation, which is why they were proposed to treat adenomyosis-related symptoms [10].”
BackgroundHorton, J., Sterrenburg, M., Lane, S., Maheshwari, A., Li, T. C., & Cheong, Y. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz012 · Cited by 376 · cited 1×
“Adenomyosis has been repeatedly associated with both poor in vitro fertilization (IVF) outcomes and pregnancy complications [79,80].”
BackgroundKitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305
Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification
Kishi, Y., Suginami, H., Kuramori, R., Yabuta, M., Suginami, R., & Taniguchi, F. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.06.027 · Cited by 301 · cited 1×
“[20]) may be more prone to developing serious menorrhagia upon dienogest administration than other disease subtypes [21].”
BackgroundGnRH and GnRH receptors in the pathophysiology of the human female reproductive system
Maggi, R., Cariboni, A. M., Marelli, M. M., Moretti, R. M., Andrè, V., Marzagalli, M., & Limonta, P. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv059 · Cited by 269 · cited 2×
“These molecules antagonize GnRH binding to its receptors, leading to dose-dependent suppression of FSH and LH and a subsequent decline in ovarian steroids [15,41].”
Background
Research works printed but not linked: 3
- Fujishita, 2010, Shikyusenkinsho to shikyu no onzon-chiryo. Uterine adenomyosis and uterine preservation treatment, J. Obstet. Gynecol. Pract., 59, 769
- Osada, 2017, Shikyukin furappuho niyoru shikyu-senkinsho tekishutsujutsu: Rinshoteki choki-yogo oyobi shikyuharetsu-yobokoka no kento. Adenomyomectomy by uterine muscle flap method: Clinical outcome and investigation of the preventive effect on uterine rupture, Obstet. Gynecol., 84, 1303
- Nishida, 2016, Shikyusenkinsho-kakushutsujutsu-go ninshin-ji no shikyuharetsu-yobo ni tsuite (Prevention of uterine rupture during pregnancy after adenomyomectomy), Obstet. Gynecol. Surg., 27, 69
Cited by
Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology
Guo, S. (2022) · Reproduction · doi:10.1530/rep-22-0224 · Cited by 100
Endometriosis and adenomyosis: Similarities and differences
Donnez, J., Stratopoulou, C. A., & Dolmans, M.-M. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2023.102432 · Cited by 57
Self-citationAdenomyosis and Adolescence: A Challenging Diagnosis and Complex Management
Martire, F. G., d’Abate, C., Schettini, G., Cimino, G., Ginetti, A., Colombi, I., Cannoni, A., Centini, G., Zupi, E., & Lazzeri, L. (2024) · Diagnostics · doi:10.3390/diagnostics14212344 · Cited by 46
“Differentiating these from benign conditions like adenomyosis requires careful imaging and, in some cases, histopathological evaluation [37,78].”
BackgroundSztachelska, M., Ponikwicka‐Tyszko, D., Martínez-Rodrigo, L., Bernaczyk, P., Palak, E., Półchłopek, W., Bielawski, T., & Wołczyński, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154407 · Cited by 41
Stratopoulou, C. A., Cussac, S., d'Argent, M., Donnez, J., & Dolmans, M. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.01.001 · Cited by 38
Self-citationResearch Advances in Adenomyosis-Related Signaling Pathways and Promising Targets
Zhang, H., Li, C., Li, W., Xin, W., & Qin, T. (2024) · Biomolecules · doi:10.3390/biom14111402 · Cited by 40
“Previous clinical treatment approaches have focused on hysterectomy, uterus sparing surgery, and medication [6].”
The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review
Moawad, G., Youssef, Y., Fruscalzo, A., Faysal, H., Kheil, M. H., Pirtea, P., Guani, B., Ayoubi, J. M., & Féki, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196130 · Cited by 35
“In their pilot study, patients with adenomyosis who were treated with 9 months of vaginal bromocriptine reported improved pain, self-image, symptom severity, and higher health-related quality of life [86].”
BackgroundConservative surgical treatment for adenomyosis: New options for looking beyond uterus removal
Capezzuoli, T., Toscano, F., Ceccaroni, M., Roviglione, G., Stepniewska, A. K., Fambrini, M., Vannuccini, S., & Petraglia, F. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2024.102507 · Cited by 26
Therapeutic options for the management of abnormal uterine bleeding
MacGregor, B., Munro, M. G., & Lumsden, M. A. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14947 · Cited by 32
Bourdon, M., Maget, A. S., Jeljeli, M. M., Doridot, L., Marcellin, L., Thomas, M., Chêne, C., Chouzenoux, S., Batteux, F., Chapron, C., et al. (2023) · Human Reproduction · doi:10.1093/humrep/dead246 · Cited by 24
An insight into gut microbiota and metabolites in the mice with adenomyosis
Chen, P., Wang, K., Zhuang, M., Fu, X., Liu, S., Chen, M., & Lei, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1075387 · Cited by 20
“The typical manifestations of AM, including abnormal uterine bleeding, pelvic pain, dysmenorrhea, and infertility, seriously reduce the quality of women’s life and work (Stratopoulou et al., 2021; Moawad et al., 2022).”
BackgroundMiao, J., Lu, J., Tang, J., & Lu, P. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2098948 · Cited by 18
“Similar to endometriosis, adenomyosis is an estrogen-dependent disorder[3].”
BackgroundKutlesic, R. M., Kutlesic, M. S., Milošević, J., Vukomanović, P., Stefanović, M., & Mostić-Stanišić, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195868 · Cited by 18
“However, dopamine agonist treatment for endometriosis/adenomyosis is not routine, and further studies are needed to clarify the use of dopamine agonists in the treatment of endometriosis-induced infertility [81].”
BackgroundAn age-period-cohort analysis of hysterectomy incidence trends in Germany from 2005 to 2019
Awuah, G. B., Schauberger, G., Klug, S. J., & Tanaka, L. F. (2024) · Scientific Reports · doi:10.1038/s41598-024-66019-8 · Cited by 16
Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies
d’Otreppe, J., Patiño-García, D., Piekos, P., de Codt, M., Manavella, D. D., Courtoy, G. E., & Orellana, R. (2024) · Endocrines · doi:10.3390/endocrines5010004 · Cited by 16
“Furthermore, symptoms tend to reappear upon treatment cessation [143].”
BackgroundInfluentialNie, J., Yi, Y., Liu, X., & Guo, S.-W. (2025) · Human Reproduction Open · doi:10.1093/hropen/hoaf028 · Cited by 11
“…adenomyosis (AD) and certain subtypes of endometriosis, such as deep endometriosis (DE), do not respond to hormonal treatment as well as ovarian endometrioma (OE) (Stratopoulou et al. , 2021; Vannuccini et al. , 2022), and aromatase inhibitors show no superior efficacy (Csirzo et al. , 2024).”
Wei, W.-J., Tian, Z.-F., Liu, H., & Xiao, C.-J. (2025) · Scientific Reports · doi:10.1038/s41598-025-85823-4 · Cited by 11
Meyer, R., Maxey, C., Hamilton, K. M., Nasseri, Y. Y., Barnajian, M., Levin, G., Truong, M., Wright, K. N., & Siedhoff, M. T. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.02.003 · Cited by 11
Stratopoulou, C. A., Grari, I. E., Camboni, A., Donnez, J., & Dolmans, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175016 · Cited by 10
“While many studies have attempted to investigate the impact of adenomyosis on fertility outcomes, none have yielded robust conclusions or led to the development of a standard medical protocol to treat the condition [9,10].”
BackgroundSelf-citationDiagnosis and Treatment of Adenomyosis with Office Hysteroscopy—A Narrative Review of Literature
Gkrozou, F., Vatopoulou, A., Skentou, C., & Paschopoulos, M. E. (2023) · Diagnostics · doi:10.3390/diagnostics13132182 · Cited by 10
“Pre-operative diagnosis of adenomyosis has been improved significantly, such as the need of offering tailored treatment depending on the patient’s age, desire for a future pregnancy, and symptomatology [31].”
BackgroundLu, K., Zhong, G., Lian, B., Zhong, X., Xie, M., & Wu, Y. (2024) · BMC Women s Health · doi:10.1186/s12905-024-03457-6 · Cited by 10
Jiang, J., Pan, Y., Yu, J., Zhang, Y., Yang, Y., Xu, H., & Sun, F. (2024) · BMC Women s Health · doi:10.1186/s12905-023-02795-1 · Cited by 9
“A surgical approach for adenomyosis may be considered when medical management fails, either due to breakthrough of pain or intol-erable side effects from drug therapy or the patient wants a definitive diagnosis [5].”
BackgroundLin, J., Liu, L., Zheng, F., Chen, S., Yang, W., Li, J., Mo, S., & Zeng, D.-Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1020757 · Cited by 8
“Studies have also reported that the standard method of managing the disease is hysterectomy, while most patients desire to preserve their fertility (Stratopoulou et al., 2021).”
MethodRisk Factors for Symptomatic Recurrence after Laparoscopic Adenomyomectomy: A 3-Year Follow-up
Sun, F., Yu, J., Pan, Y., Huo, X., Yang, Y., & Xu, H. (2023) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2023.03.001 · Cited by 8
Nonsurgical management of adenomyosis: an overview of current evidence
Lazaridis, A., Grammatis, A. L., Spencer, S., & Hirsch, M. (2022) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000810 · Cited by 8
Manu, A., Poenaru, E., Duică, F., Stoleru, S., Bauşic, A. I. G., Coroleuca, B.-C., Coroleucă, C. A., Iacob, C. M., & Brătilă, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207256 · Cited by 9
“- Conservative surgery (for focal adenomyomas) - Hysterectomy (definitive treatment for women not desiring future fertility) [41–43]”
Characterization of patients that can continue conservative treatment for adenomyosis
Miyagawa, C., Murakami, K., Tobiume, T., Nonogaki, T., & Matsumura, N. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01577-x · Cited by 6
Adenomyomectomy: A complicated surgery
Li, Y., Seow, K., & Wang, P. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2022.03.001 · Cited by 6
Factors associated with deep infiltrating endometriosis, adenomyosis and ovarian endometrioma
Yuan, X., Wong, B. W., Randhawa, N., Thu, W. P. P., Chan, Y. H., Ma, L., & Yong, E. (2023) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2022334 · Cited by 7
The role of progestin subdermal implant in the management of adenomyosis: a systematic review
Chene, G., Baffet, H., Cerruto, E., Nohuz, E., & Agostini, A. (2024) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2024.2314298 · Cited by 6
“Adenomyosis is an oestrogen-dependent benign uterus disease with an estimated prevalence of 20-30% [1,2].”
BackgroundTreatment-related changes in adenomyosis: a primer for radiologists
Oliveira, B. C., Feldman, . K., Jha, P., Young, S. W., Cambiaghi, A. S., & Chamié, L. P. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-04866-3 · Cited by 4
“Treatment decisions are based on the patient’s age, symptom severity, and reproductive goals, with options varying from long-term medical therapy, which may continue even after menopause, to hysterectomy (8, 13).”
Su, Z., Liu, S., Wang, J., Jin, F., Peng, Y., & Wen, J. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-04908-w · Cited by 3
Uterine rupture due to adenomyosis in an adolescent: A case report and review of literature
Kim, N. I., Lee, J. S., & Nam, J. H. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i32.7888 · Cited by 3
Activation of HAND2-FGFR signaling pathway by lncRNA HAND2-AS1 in adenomyosis
Zheng, Y., Wu, S. L., Liu, L., Guan, Y., Sun, W., Miao, C., & Li, Q. (2023) · Biology of Reproduction · doi:10.1093/biolre/ioad171 · Cited by 3
“Hence, progestins are often used clinically to support pregnancy and alleviate pain in women with adenomyosis [10].”
BackgroundLiu, S., Peng, C., Wang, Z., Zhou, X. K., Zhang, S., Li, G., & Yang, B. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15779 · Cited by 2
Histopathological Diversity in Hysterectomy Specimens at Jinnah Sindh Medical University Lab
Adnan, M., Hussain, W., Zaidi, Y. A., Zeeshan, F., Sultan, B. A., & Parween, S. (2025) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v6i7.3167 · Cited by 2
Park, H.-S., Jeong, H. I., Kim, K. H., Yang, S., & Roh, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1679449 · Cited by 2
Adenomiose: aspectos epidemiológicos, fisiopatológicos e manejo terapêutico
Figueira, A. M. D. A., Pinto, C. M. C., Oliveira, E. A. R. D., Nascimento, F. H., de Andrade, J. P. L. M., Zica, L. S., Miranda, L. A., de Carvalho, L. A. S. M., Affonso, M. C., & FRAGA, T. P. (2023) · Brazilian Journal of Development · doi:10.34117/bjdv9n3-054 · Cited by 2
Agonists of gonadotropin-releasing-hormone and add-back-therapy
Pustotina, O. A. (2023) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush20232302163 · Cited by 2
Liu, X., Wang, J., Liu, Y., Luo, S., Yan, G., Yang, H., Wan, L., & Huang, G. (2023) · Diagnostics · doi:10.3390/diagnostics13091608 · Cited by 2
Liang, Y., Xiao, T., & Zhang, H. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00852-z · Cited by 4
“However, regarding long‐term outcomes, conservative treatment is associated with a higher recurrence rate, whereas hysterectomy can provide a definitive cure, albeit at the cost of permanent loss of fertility [30].”
Novel exploration of Raman microscopy and non-linear optical imaging in adenomyosis
Shen, Z., He, Y., Shen, Z.-Y., Wang, X., Wang, Y., Hua, Z., Jiang, N., Song, Z., Li, R., & Xiao, Z. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.969724 · Cited by 2
Zhu, Q., Cao, S., Wang, Q., Xu, J., & Hu, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1606074 · Cited by 1
Effect of Elagolix in comparison to Dienogest in the treatment of symptomatic adenomyosis
Jubaida, U., Deeba, F., Ishrat, S., Anwary, S. A., Sultana, R., Alamgir, C. F., Darmini, M., & Banu, J. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20251977 · Cited by 1
Is endometriosis a progressive disease?
Guo, S., Canis, M. J., & Vercellini, P. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.02.011 · Cited by 2
Fertility in adenomyosis: surgery or IVF?
Chandra, S., Tjahyadi, D., Rachmawati, A., & Syam, H. H. (2026) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.26.05874-4 · Cited by 1
Kobayashi, H. (2026) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-026-01588-z · Cited by 2
“Furthermore, the substantial overlap in current therapeutic strategies for endometriosis and adenomyosis reflects the shared biological characteristics of these disorders, including their estrogen dependence [10, 11].”
Shalina, M. A., & Yarmolinskaya, M. I. (2025) · Journal of obstetrics and women s diseases · doi:10.17816/jowd641737 · Cited by 1
(2022) · Gynäkologische Endokrinologie · doi:10.1007/s10304-022-00446-6
Clinical Research Progress of Adenomyosis
席, 欣. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121707
(2023) · Journal of Gynecology & Reproductive Medicine · doi:10.33140/jgrm.07.01.04
Medical treatment of adenomyosis: a literature review
Tskhay, V. B., Александровна, Б. А., & Mikailli, G. T. (2023) · GYNECOLOGY · doi:10.26442/20795696.2023.2.202101
“Это является ключевым преимуществом антагонистов ГнРГ в терапии пациентов, желающих сохранить фертильность, по сравнению с агонистами ГнРГ [44].”
Adenomiosis: una mirada a esta compleja patología ginecológica
González-González, F., & Rivera-Gómez, A. (2023) · Revista Medica Sinergia · doi:10.31434/rms.v8i8.1086
Hagiwara, T., 小堀, 宏., Kato, N., Noji, C., Yamamoto, N., & Kumakiri, Y. (2024) · JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY · doi:10.5180/jsgoe.40.1_36
Alonso, A., Budden, A., & Abbott, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21477-6.00238-8
Operative treatment for adenomyosis: update on literature review
Winata, G. S., Suardika, A., Mahayasa, P. D., Budiana, N. G., & Kamajaya, I. G. N. A. T. (2024) · Indonesian Journal of Perinatology · doi:10.51559/inajperinatol.v5i2.58
Adenomiosis. Revisión Narrativa de Factores de Riesgo, Diagnóstico y Tratamiento
Maracaibo-Venezuela, U. D. Z., & Núñez-Troconis, J. (2024) · Revista de Obstetricia y Ginecología de Venezuela · doi:10.51288/00840415 · Cited by 1
“La eficacia de los análogos en la reducción del tamaño del útero al inducir amenorrea y por tanto el dolor ha sido demostrado desde hace 3 décadas (72, 73).”
InfluentialManagement of abnormal uterine bleeding in primary care
Horne, M., & Martin, K. (2025) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000362
Treatment selection for adenomyosis based on imaging findings and patient characteristics
Kobayashi, H. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70992
“9 While these treatments are central to symptom control and uterine preservation, treatment response and long-term tolerability vary substantially, limiting the effectiveness of uniform therapeutic strategies.”
Güzelbağ, B., & Bahat, P. Y. (2026) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.70329
“%) is consistent with growing evidence of significant angiogenic activity in adenomyosis, potentially contributing to characteristic bleeding patterns and representing therapeutic targets for antiangiogenic interventions [7, 29].”
Li, F., Wang, H. J., Zhang, Y., Nan, F., Xu, L., Liu, Z. Y., & Shi, W. (2026) · Seminars in Immunopathology · doi:10.1007/s00281-026-01077-w
“In addition, due to the fact that progesterone can inhibit the secretion of FSH and LH and ultimately inhibit the forma - tion of ovarian steroids and alleviate the excessive estrogen production associated with adenomyosis, this hormone is also used for the treatment of adenomyosis [291].”
Epidemiology of endometriosis and adenomyosis
Upson, K., Missmer, S. A., Tellum, T., Harris, H. R., & As‐Sanie, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00031-7
Donnez, J., Donnez, O., Taylor, H. S., Petraglia, F., Horne, A. W., Becker, C. M., Renner, S. P., Rius, M., Bestel, E., Stratopoulou, C. A., et al. (2026) · Reproduction and Fertility · doi:10.1530/raf-26-0075 · Cited by 1
Self-citationMetabolic reprogramming in adenomyosis: a systematic review of metabolomics studies
Michele, S. D., Camoglio, C., Nappi, L., Tinelli, R., Daniilidis, A., Grimbizis, G., & Angioni, S. L. (2026) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2026.115465
Pecorella, G., Morciano, A., & Tinelli, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27757-3.00017-1
Ding, K., Tian, C., Zhu, Q., Sang, C., & Zhao, S. (2026) · International Journal of Hyperthermia · doi:10.1080/02656736.2026.2758035
Metadata
- Authors
- Stratopoulou, C. A., Donnez, J., & Dolmans, M.-M.
- Affiliations
- UCLouvain (BE)
- Cliniques Universitaires Saint-Luc (BE)
- Corresponding author
- Dolmans, Marie-Madeleine
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-10-22
- Volume
- 10
- Issue
- 21
- Pages
- 4878
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC8584979
- OpenAlex
- W3210890914
- Cited by
- 62
- References
- 103
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 13 · 2023: 18 · 2022: 9 · 2021: 1
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fonds National de la Recherche Scientifique de Belgique (5/4/150/5)
- PregLem via the Fondation Saint-Luc (N/A)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- uterine adenomyosis, conservative treatment, medical management, surgical management, fertility preservation, hysterectomy, menorrhagia, pelvic pain, infertility, nulliparous women, uterine rupture, GnRH antagonist, off-label drug use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.